Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director Richard S. Levy sold 11,000 shares of the company's stock in a transaction on Monday, April 1st. The stock was sold at an average price of $257.48, for a total transaction of $2,832,280.00. Following the sale, the director now directly owns 10,298 shares of the company's stock, valued at $2,651,529.04. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Madrigal Pharmaceuticals Stock Performance
Shares of MDGL stock opened at $245.23 on Thursday. Madrigal Pharmaceuticals, Inc. has a 52-week low of $119.76 and a 52-week high of $322.67. The company has a debt-to-equity ratio of 0.28, a quick ratio of 5.38 and a current ratio of 5.38. The firm has a fifty day moving average of $238.80 and a 200-day moving average of $203.44.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($5.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.26) by ($0.42). During the same period last year, the business posted ($4.98) EPS. On average, equities research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -21.48 earnings per share for the current year.
Wall Street Analyst Weigh In
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing | Ad
“Titan of Tech” Bets Big on Tiny AI Company
He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal…
But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
A number of brokerages have weighed in on MDGL. UBS Group increased their price target on shares of Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the company a "buy" rating in a report on Friday, March 15th. HC Wainwright increased their price target on shares of Madrigal Pharmaceuticals from $405.00 to $425.00 and gave the company a "buy" rating in a report on Friday, March 15th. Canaccord Genuity Group increased their price target on shares of Madrigal Pharmaceuticals from $338.00 to $377.00 and gave the company a "buy" rating in a report on Friday, March 15th. Evercore ISI increased their price target on shares of Madrigal Pharmaceuticals from $325.00 to $405.00 and gave the company an "outperform" rating in a report on Wednesday, March 20th. Finally, StockNews.com raised shares of Madrigal Pharmaceuticals to a "sell" rating in a report on Thursday, March 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $377.40.
Check Out Our Latest Stock Analysis on MDGL
Institutional Investors Weigh In On Madrigal Pharmaceuticals
Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its position in shares of Madrigal Pharmaceuticals by 21.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the biopharmaceutical company's stock worth $301,000 after purchasing an additional 367 shares in the last quarter. Glenmede Trust Co. NA increased its position in shares of Madrigal Pharmaceuticals by 53.2% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,567 shares of the biopharmaceutical company's stock worth $229,000 after purchasing an additional 544 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter worth about $314,000. Charles Schwab Investment Management Inc. increased its position in shares of Madrigal Pharmaceuticals by 11.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 109,501 shares of the biopharmaceutical company's stock worth $15,992,000 after purchasing an additional 11,083 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Madrigal Pharmaceuticals by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,573,338 shares of the biopharmaceutical company's stock worth $229,770,000 after purchasing an additional 107,816 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
